Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation A Phase 3b, Randomized, Placebo-controlled Study
- Mall, M.A.
- Brugha, R.
- Gartner, S.
- Legg, J.
- Moeller, A.
- Mondejar-Lopez, P.
- Prais, D.
- Pressler, T.
- Ratjen, F.
- Reix, P.
- Robinson, P.D.
- Selvadurai, H.
- Stehling, F.
- Ahluwalia, N.
- Arteaga-Solis, E.
- Bruinsma, B.G.
- Jennings, M.
- Moskowitz, S.M.
- Noel, S.
- Tian, S.
- Weinstock, T.G.
- Wu, P.
- Wainwright, C.E.
- Davies, J.C.
ISSN: 1535-4970, 1073-449X
Any de publicació: 2022
Volum: 206
Número: 11
Pàgines: 1361-1369
Tipus: Article